论文部分内容阅读
OBJECTIVE To evaluate the therapeutic effect and potential adverse effects of sodium ibandronate (SI) in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups. Group A (SI) of 68 patients who received 4 mg SI I.v., and 73 patients in Group B (pamidronate disodium [PD]) who received 60 mg PD I.v. A randomized, double-blind method, with PD as a positive drug control, was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrolled in the study, with 136 cases of appraisable efficacy. The effective rate was 72.3% (47/65) in Group A, and 63.4% (45/71) in Group B. There was no significant difference in efficacy or adverse effects between the 2 groups. CONCLUSION The SI injection, with a pronounced effect, can relieve bone pain caused by osseous metastasis from a malignant tumor. The curative and adverse effects were similar compared to PD.